Molecular Cloning of a New Transforming Gene from a Chemically Transformed Human Cell Line

Overview

Journal Nature

Specialty Science

Date 1984 Sep 6

PMID 6590967

Citations 320

Authors

C S Cooper

M Park

D G Blair

M A Tainsky

K Huebner

C M Croce

G F Vande Woude

Affiliations

Soon will be listed here.

Abstract

Molecular cloning of the transforming gene from a chemically transformed human osteosarcoma-derived cell line enables the gene to be mapped to chromosome 7 (7p11.4-7qter) and by this criterion and by direct hybridization to be shown to be unrelated to known oncogenes.

Citing Articles

Mapping kinase domain resistance mechanisms for the MET receptor tyrosine kinase via deep mutational scanning.

Estevam G, Linossi E, Rao J, Macdonald C, Ravikumar A, Chrispens K Elife. 2025; 13.

PMID: 39960754 PMC: 11832172. DOI: 10.7554/eLife.101882.

Comprehensive bioinformatics analysis of selected germline variants of uncertain significance identified in a cohort of Sri Lankan hereditary breast cancer patients.

Arachchige N, Sirisena N, De Silva S, Senathilake K, Faizan M, Dissanayake V Hum Genomics. 2025; 19(1):12.

PMID: 39940038 PMC: 11823233. DOI: 10.1186/s40246-024-00703-8.

Characterization of Bozitinib as a potential therapeutic agent for MET-amplified gastric cancer.

Lin H, Qu L, Wei H, Guo M, Chen X, Lin Q Commun Biol. 2025; 8(1):134.

PMID: 39875456 PMC: 11775172. DOI: 10.1038/s42003-025-07490-5.

MET Activation in Lung Cancer and Response to Targeted Therapies.

Okun S, Lu D, Sew K, Subramaniam A, Lockwood W Cancers (Basel). 2025; 17(2).

PMID: 39858062 PMC: 11764361. DOI: 10.3390/cancers17020281.

Development of dual aptamers-functionalized c-MET PROTAC degraders for targeted therapy of osteosarcoma.

Fu X, Huang J, Chen X, Xie D, Chen H, Liang Z Theranostics. 2025; 15(1):103-121.

PMID: 39744222 PMC: 11667235. DOI: 10.7150/thno.99588.